ARC Innovation at Sheba Medical Center and Icahn School of Medicine at Mount Sinai (part of the Mount Sinai Health System in New York City) today announced a landmark three-year collaboration with NVIDIA to harness the power of artificial intelligence for genomic discovery through the application of large language model (LLM) technology. The initiative aims to pioneer the decoding of the majority of the human genome that remains poorly understood in order to unlock new pathways for disease prevention, diagnosis, and treatment. Over the three-year period, the project will be supported by significant investment from the participating organizations, with the goal of accelerating research that can ultimately benefit patients worldwide.

A research team has tested how well three large language models can detect overlaps and redundancies in clinical questionnaires on mental illness / publication in ‘Nature Mental Health’

Apriori Bio, a Flagship Pioneering portfolio company, and the Agency for Science, Technology and Research Infectious Diseases Labs (A*STAR IDL) have announced a research collaboration to co-develop self-amplifying RNA (saRNA) vaccine candidates targeting H5 influenza. The partnership combines Apriori’s Octavia™ AI-guided antigen-design platform with A*STAR IDL’s saRNA delivery technology and infectious-disease expertise, advancing breakthrough solutions for the advancement of human health, supporting the development of next-generation vaccines and contributing to Singapore’s growth as a global hub for biomedical innovation.